drugset / Trial / NCT04173338
Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma
NaSingle-groupOpen-labelTreatment
Summary
This study will combine cabozantinib with pemetrexed to treat patients with non-small cell lung cancer, urothelial cancer and advanced malignant mesothelioma. This study will test the safety of both drugs used together and see what effect (good or bad) it has no participants and their cancer.
Timeline
- Start
- 2020-01-23
- Primary completion
- 2022-03-28
- Completion
- 2022-03-28
Outcome
Outcome not reported
Stopped: “Closed by IRB on 3/28/22”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cabozantinib | Small molecule | 20 mg | Oral |
| Subject | Cabozantinib | Small molecule | 40 mg | Oral |
| Subject | Cabozantinib | Small molecule | 60 mg | Oral |
| Subject | Pemetrexed | Small molecule | 500 mg/m2 | Intravenous |